📊 TRVI Key Takeaways
Is Trevi Therapeutics, Inc. (TRVI) a Good Investment?
Trevi Therapeutics is a pre-revenue biopharmaceutical company burning $16.7M annually with only $19.4M in cash, implying approximately 1 year of financial runway. While the balance sheet is strong with minimal debt and $172.1M in equity, the company faces existential execution risk dependent on successful clinical development and capital raises.
Why Buy Trevi Therapeutics, Inc. Stock? TRVI Key Strengths
- Fortress balance sheet with $172.1M stockholders equity and near-zero liabilities ($7.5M)
- Exceptional liquidity position with 24.75x current ratio eliminating near-term bankruptcy risk
- Improving loss trajectory with net loss declining 31.9% year-over-year, suggesting operational optimization
TRVI Stock Risks: Trevi Therapeutics, Inc. Investment Risks
- Zero revenue with no approved commercial products, representing fundamental business model risk
- Operating cash burn of $16.7M annually exhausts current cash reserves within approximately 12 months
- Pre-commercial execution risk: success entirely dependent on clinical trial outcomes, FDA approval, and future capital availability
- Negative returns (ROE -7.7%, ROA -7.3%) with no current path to profitability without product launches
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash balance - determines capital raise urgency
- Clinical pipeline advancement and FDA regulatory interactions for lead candidates
- Dilution impact and terms of future equity financing rounds
Trevi Therapeutics, Inc. (TRVI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 24.75x current ratio provides a solid financial cushion.
TRVI Profit Margin, ROE & Profitability Analysis
TRVI vs Healthcare Sector: How Trevi Therapeutics, Inc. Compares
How Trevi Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Trevi Therapeutics, Inc. Stock Overvalued? TRVI Valuation Analysis 2026
Based on fundamental analysis, Trevi Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Trevi Therapeutics, Inc. Balance Sheet: TRVI Debt, Cash & Liquidity
TRVI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Trevi Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.47 indicates the company is currently unprofitable.
TRVI Revenue Growth, EPS Growth & YoY Performance
Trevi Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TRVI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Trevi Therapeutics, Inc. (CIK: 0001563880)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TRVI
What is the AI rating for TRVI?
Trevi Therapeutics, Inc. (TRVI) has an AI rating of SELL with 50% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TRVI's key strengths?
Claude: Fortress balance sheet with $172.1M stockholders equity and near-zero liabilities ($7.5M). Exceptional liquidity position with 24.75x current ratio eliminating near-term bankruptcy risk.
What are the risks of investing in TRVI?
Claude: Zero revenue with no approved commercial products, representing fundamental business model risk. Operating cash burn of $16.7M annually exhausts current cash reserves within approximately 12 months.
What is TRVI's revenue and growth?
Trevi Therapeutics, Inc. reported revenue of N/A.
Does TRVI pay dividends?
Trevi Therapeutics, Inc. does not currently pay dividends.
Where can I find TRVI SEC filings?
Official SEC filings for Trevi Therapeutics, Inc. (CIK: 0001563880) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TRVI's EPS?
Trevi Therapeutics, Inc. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TRVI a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Trevi Therapeutics, Inc. has a SELL rating with 50% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TRVI stock overvalued or undervalued?
Valuation metrics for TRVI: ROE of -7.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TRVI stock in 2026?
Our dual AI analysis gives Trevi Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TRVI's free cash flow?
Trevi Therapeutics, Inc.'s operating cash flow is $-16.7M, with capital expenditures of $102.0K.
How does TRVI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -7.7% (avg: 15%), current ratio 24.75 (avg: 2).